Be part of the knowledge.™

Global Oncology Academy

The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.

For more information about GOA, visit www.globaloncologyacademy.org.

876

LikeLikedUnlike

16-30 of 395

Case: Implementing ADT Intensification in mHSPC
MinuteCE®
Case: Implementing ADT Intensification in mHSPC
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credits
Targeting PTEN: Why It Matters
MinuteCE®
Targeting PTEN: Why It Matters
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credits
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Oncology and Hematology
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
- Nicolas Girard, MD
- Louise Lim, MD
- Jacob Sands, MD
- Stephanie McDonald, MSN, FNP-BC, AOCNP
Addressing Oncology-Related Infertility Through Collaborative Care
Clinician's Roundtable
Addressing Oncology-Related Infertility Through Collaborative Care
- Irene Su, MD, MSCE
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Project Oncology®
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
- Steve Jackson, PharmD
- Lyudmila A. Bazhenova, MD
Assessing and Interpreting pCR in Perioperative NSCLC
Project Oncology®
Assessing and Interpreting pCR in Perioperative NSCLC
- Steve Jackson, PharmD
- Alexander Spira, MD, PhD, FACP
advertisement
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
- Erica L. Mayer, MD, MPH
0.50 program credits
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®
Key Differences in Pulmonary and Extrapulmonary NEC Management
- Alexandria May, PharmD, BCPS
- Lowell B. Anthony, MD, FACP
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Project Oncology®
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
- Alexandria May, PharmD, BCPS
- Chandrikha Chandrasekharan, MBBS
advertisement
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
- Sara A. Hurvitz, MD, FACP
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Project Oncology®
Navigating Classification of High-Grade Neuroendocrine Neoplasms
- Charles Turck, PharmD, BCPS, BCCCP
- Rohit Thummalapalli, MD
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
- Tiffany Traina, MD, FASCO

Program Chapters

Segment Chapters

Playlist:

Recommended